Regulus Therapeutics Statistics
Share Statistics
Regulus Therapeutics has 69.23M
shares outstanding. The number of shares has increased by 1.19%
in one year.
| Shares Outstanding | 69.23M |
| Shares Change (YoY) | 1.19% |
| Shares Change (QoQ) | 1.13% |
| Owned by Institutions (%) | 81.73% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 4,477 |
| FTD / Avg. Volume | 0.23% |
Short Selling Information
The latest short interest is 2.71M, so 4.09% of the outstanding
shares have been sold short.
| Short Interest | 2.71M |
| Short % of Shares Out | 4.09% |
| Short % of Float | 5.18% |
| Short Ratio (days to cover) | 1 |
Valuation Ratios
The PE ratio is -1.92 and the forward
PE ratio is -5.65.
Regulus Therapeutics's PEG ratio is
0.04.
| PE Ratio | -1.92 |
| Forward PE | -5.65 |
| PS Ratio | 0 |
| Forward PS | 0.4 |
| PB Ratio | 1.17 |
| P/FCF Ratio | -2.12 |
| PEG Ratio | 0.04 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Regulus Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 10.98,
with a Debt / Equity ratio of 0.
| Current Ratio | 10.98 |
| Quick Ratio | 10.98 |
| Debt / Equity | 0 |
| Debt / EBITDA | -0.01 |
| Debt / FCF | -0.01 |
| Interest Coverage | -316.71 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-1,363,470.59 |
| Employee Count | 34 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 1K |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by 288.12% in the
last 52 weeks. The beta is 0.5, so Regulus Therapeutics's
price volatility has been higher than the market average.
| Beta | 0.5 |
| 52-Week Price Change | 288.12% |
| 50-Day Moving Average | 3.12 |
| 200-Day Moving Average | 1.9 |
| Relative Strength Index (RSI) | 91.56 |
| Average Volume (20 Days) | 1,921,806 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -50.04M |
| Net Income | -46.36M |
| EBITDA | -45.85M |
| EBIT | -46.2M |
| Earnings Per Share (EPS) | -0.82 |
Full Income StatementBalance Sheet
The company has 38.53M in cash and 274K in
debt, giving a net cash position of 38.25M.
| Cash & Cash Equivalents | 38.53M |
| Total Debt | 274K |
| Net Cash | 38.25M |
| Retained Earnings | -559.57M |
| Total Assets | 84.18M |
| Working Capital | 74.85M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -41.67M
and capital expenditures -340K, giving a free cash flow of -42.01M.
| Operating Cash Flow | -41.67M |
| Capital Expenditures | -340K |
| Free Cash Flow | -42.01M |
| FCF Per Share | -0.75 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
